Latest Headlines

Latest Headlines

Valeant chief shoots for $10B in sales--and then $20B

You can't fault Valeant Pharmaceuticals ($VRX) CEO Michael Pearson for thinking small. In an analyst call, Pearson not only predicted that 2013 revenue would hit up to $4.8 billion, up from an expected $3.4 billion to $3.6 billion in 2012; he also said Valeant could top $10 billion in annual sales. It could even hit $20 billion.

IntelGenx looks to mimic Biovail's success

With its bevy of drug delivery platforms and recent success in Big Pharma partnerships, IntelGenx is looking to duplicate the success of Biovail, CEO Horst Zerbe said.

Canada bars Biovail founder Melnyk from executive office

Biovail founder Eugene Melnyk (photo) will be persona non grata in Canadian public company circles for a while. The Ontario Securities Commission (OSC), Canada's securities regulator, barred Melnyk

Court rules in IntelGenx's favor in Wellbutrin-maker's lawsuit

Quebec-based IntelGenx received a positive ruling Tuesday in a case involving two patents owned by Biovail Laboratories, the maker of the antidepressant Wellbutrin XL. The U.S. District Court of

In wake of chairman's exit, Valeant CFO resigns

'Tis the time of year for executive turmoil, apparently. Valeant Pharmaceuticals ($VRX) CFO Peggy Mulligan resigned abruptly, just a week after Chairman Bill Wells departed. This means the company is

Acadia, Biovail end Parkinson's drug deal

Acadia Pharmaceuticals and Biovail, a subsidiary of Valeant Pharmaceuticals, said this morning that they have ended the collaboration agreement on pimavanserin, a drug for Parkinson's. Last year the

Lawmakers object to Biovail-Valeant merger

Maybe the soon-to-merge Valeant Pharmaceuticals and Biovail shouldn't have talked so openly about plans to lay off a big chunk of the combined workforce. On the eve of a shareholder vote to approve

Good news: Merck to add 310 jobs; bad news: Biovail/Valeant to cut 1,100

It promised North Carolina 440 jobs in two years to meet increased demand for its vaccines. Merck now says it will add 310 more. "We have grown much faster than anyone had anticipated," says plant

Shionogi cutting 350 reps as Biovail boosts layoffs

We've got news for those of you keeping tabs on pharma layoffs. Not only have Valeant and Biovail announced that their planned post-merger job cuts will amount to 25 percent of the combined

Biovail-Valeant combo will cost 25% of all jobs

When the execs at Biovail and Valeant sat down with analysts last June to hype their approaching reverse merger, one of the highlights of their discussion focused on the $175 million in cost